PCSK9 inhibition with alirocumab, on top of high-intensity statin therapy, resulted in significant coronary plaque regression among patients with familial hypercholesterolemia and no clinical atherosclerotic CVD, researchers reported.The results of the phase 4, open-label, multicenter, single-arm ARCHITECT study were published in Circulation.